Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells

被引:73
作者
Nguyen, DM
Schrump, WD
Chen, GA
Tsai, W
Nguyen, P
Trepel, JB
Schrump, DS
机构
[1] NCI, Thorac Oncol Sect, Surg Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Clin Res Unit, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-0901-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Recent insights regarding the pathogenesis of malignant pleural mesothelioma (MPM) provide new opportunities for targeted molecular therapies for this highly lethal disease. The present study was undertaken to examine the effects of the histone deacetylase inhibitor, Depsipeptide (DP) FK228, in conjunction with the cyclin-dependent kinase inhibitor, Flavopiridol (FLA), in cultured MPM cells. Experimental Design: Proliferation and apoptosis in drug-treated, virally transduced, or control cells were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Apo-bromodeoxyuridine techniques. Western blot and ELISA techniques were used to examine signal transduction and cell cycle-related protein levels in MPM cells exposed to DP and/or FLA in the presence or absence of calphostin, phorbol-12,13-dibutyrate, 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole, or adenoviral p21 transduction. Results: DP (1-50 ng/ml x 6 h) or FLA (100-200 nM x 72 h) alone, mediated low-level, dose-dependent growth inhibition in MPM cells. In contrast, sequential DP/FLA treatment mediated marked growth inhibition and apoptosis in these cell lines. The cytotoxic effects of DP/FLA were considerably less pronounced in cultured normal cells. The proapoptotic effects of DP/FLA treatment coincided with inhibition of DP-mediated induction of p21 by FLA. Overexpression of p21 by adenoviral gene transfer techniques rendered MPM cells refractory to the cytotoxic effects of this treatment regimen. In p21 reporter assays, promoter activation by DP was antagonized by FLA. The magnitude of inhibition of DP-mediated p21 induction by FLA exceeded that observed with the pTEFb antagonist 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole. Calphostin C abrogated p21 induction mediated by DP and enhanced DP-mediated apoptosis in a manner comparable with FLA in MPM cells; in contrast, phorbol-12,13-dibutyrate blocked FLA-mediated inhibition of p21 induction by DP and markedly protected these cells from the apoptotic effects of sequential DP/FLA. Conclusions: FLA abrogates DP-mediated induction of p21 expression, in part, via inhibition of protein kinase C signaling and markedly potentiates the cytotoxic effects of DP in MPM cells.
引用
收藏
页码:1813 / 1825
页数:13
相关论文
共 53 条
[41]   Procaspase 3/p21 complex formation to resist Fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A [J].
Suzuki, A ;
Kawano, H ;
Hayashida, M ;
Hayasaki, Y ;
Tsutomi, Y ;
Akahane, K .
CELL DEATH AND DIFFERENTIATION, 2000, 7 (08) :721-728
[42]  
Suzuki A, 1999, MOL CELL BIOL, V19, P3842
[43]   Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death [J].
Suzuki, A ;
Ito, T ;
Kawano, H ;
Hayashida, M ;
Hayasaki, Y ;
Tsutomi, Y ;
Akahane, K ;
Nakano, T ;
Miura, M ;
Shiraki, K .
ONCOGENE, 2000, 19 (10) :1346-1353
[44]   Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21 [J].
Suzuki, A ;
Tsutomi, Y ;
Miura, M ;
Akahane, K .
ONCOGENE, 1999, 18 (05) :1239-1244
[45]   SV40 and cell cycle perturbations in malignant mesothelioma [J].
Testa, JR ;
Giordano, A .
SEMINARS IN CANCER BIOLOGY, 2001, 11 (01) :31-38
[46]  
Testa JR, 2001, CANC PRINCIPLES PRAC, P1937
[47]   Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells [J].
Toyooka, S ;
Carbone, M ;
Toyooka, K ;
Bocchetta, M ;
Shivapurkar, N ;
Minna, JD ;
Gazdar, AF .
ONCOGENE, 2002, 21 (27) :4340-4344
[48]  
UEDA H, 1994, J ANTIBIOT, V47, P301
[49]  
Waheed I, 1999, CANCER RES, V59, P6068
[50]  
Wall NR, 2003, CANCER RES, V63, P230